To further verify whether CSNK1D affected tumor development through the HH pathway, we applied the agonists of the HH pathway (SAGs) into the CSNK1D-knockdown CAL27 or HN4 cells, and the HH pathway inhibitor (SANT1) into CSNK1D-overexpressed cells. Here, CSNK1D is linked to neoplasm.